{"id":"W3170157997","doi":"10.1007/s40273-021-01027-4","title":"Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Novartis Pharmaceuticals Corporation","keywords":"Fulvestrant; Medicine; Hazard ratio; Oncology; Metastatic breast cancer; Discontinuation; Internal medicine; Breast cancer; Cancer; Progression-free survival; Quality-adjusted life year; Letrozole; Cost effectiveness; Gynecology; Estrogen receptor; Tamoxifen; Confidence interval; Overall survival","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001912786,0.0008693811,0.001172927,0.001761783,0.0007824353,0.003134198,0.001258787,0.001858744,0.006756132],"category_scores_gemma":[0.007413908,0.0003438652,0.002493148,0.002770507,0.0007752606,0.0007416935,0.0006494431,0.002603825,0.0003269522],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.05447413,"about_ca_system_score_gemma":0.05079442,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.8478913,"about_ca_topic_score_gemma":0.9010628,"domain_scores_codex":[0.9978829,0.0006780805,0.00009348358,0.0001309645,0.00081399,0.0004005617],"domain_scores_gemma":[0.9961434,0.001071697,0.0005272976,0.00003939159,0.00138465,0.0008336318],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.01709215,0.0008293386,0.05847944,0.006676107,0.01101276,0.001746256,0.0004444477,0.08741268,0.003308239,0.04902795,0.2081845,0.5557861],"study_design_scores_gemma":[0.01381965,0.00734753,0.4142192,0.01703869,0.03300772,0.003581579,0.003839324,0.0759594,0.002035234,0.02748698,0.4008446,0.000820148],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.1645188,0.3925055,0.002231918,0.2850596,0.002259997,0.000377016,0.02142007,0.0001593414,0.1314678],"genre_scores_gemma":[0.8241627,0.1415361,0.002856578,0.01843306,0.00196637,0.0000874845,0.004983015,0.00004490857,0.005929806],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.1521087,"threshold_uncertainty_score":0.3952394,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03336379531504483,"score_gpt":0.35892055458306,"score_spread":0.3255567592680152,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}